Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Status
The amended claim set filed 21 July 2026 is acknowledged. Claims 8-11 and 19-33 are currently pending. Of those, claims 10, 19, 21-23, 25-31, and 33 are currently amended, and no claims are new. Claims 1-7 and 12-18 are cancelled. Claims 8-11 and 19-33 are subject to restriction requirement.
Claims 8-11 and 33 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was provisionally made without traverse in the telephone call on 17 Sep 2026 (see below). Claims 19-32 are examined on the merits herein.
Election/Restriction
REQUIREMENT FOR UNITY OF INVENTION
As provided in 37 CFR 1.475(a), a national stage application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept (“requirement of unity of invention”). Where a group of inventions is claimed in a national stage application, the requirement of unity of invention shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features. The expression “special technical features” shall mean those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art.
The determination whether a group of inventions is so linked as to form a single general inventive concept shall be made without regard to whether the inventions are claimed in separate claims or as alternatives within a single claim. See 37 CFR 1.475(e).
When Claims Are Directed to Multiple Categories of Inventions:
As provided in 37 CFR 1.475 (b), a national stage application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combinations of categories:
(1) A product and a process specially adapted for the manufacture of said product; or
(2) A product and a process of use of said product; or
(3) A product, a process specially adapted for the manufacture of the said product, and a use of the said product; or
(4) A process and an apparatus or means specifically designed for carrying out the said process; or
(5) A product, a process specially adapted for the manufacture of the said product, and an apparatus or means specifically designed for carrying out the said process.
Otherwise, unity of invention might not be present. See 37 CFR 1.475 (c).
Restriction is required under 35 U.S.C. 121 and 372.
This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.
In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.
Group 1, claim(s) 8-11, drawn to a pharmaceutical composition comprising a specific O-antigen structure.
Group 2, claim(s) 19-32, drawn to methods comprising administering generic O-antigen.
Group 3, claim(s) 33, drawn to a method of determining a prognosis of a subject having sepsis induced by a Gram-negative bacterial infection, the method comprising detecting a presence of transitional premonocytes (TpMos) in a blood sample obtained from the subject.
The groups of inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:
Groups 1 and 2 lack unity of invention because even though the inventions of these groups require the technical feature of a pharmaceutical composition comprising O-antigen, this technical feature is not a special technical feature as it does not make a contribution over the prior art in view of Anderson et al. (US-20220152181-A1; made of record in IDS filed 2 Sep 2025). Anderson teaches a composition that “further includes a saccharide selected from any saccharide having a Formula in Table 1” [0011]. Table 1 is a table of O antigen structures [title of Table 1 following par. 0365], and includes that the O antigens from E. coli O18 and O111 comprise the structure DGlc-(al-4)-DGal(al-3)-DGlcNAc.
Groups 1 and 3 lack unity of invention because the groups do not share the same or corresponding technical feature. Group 1 is drawn to a O-antigen composition and Group 3 does not include O-antigen.
Groups 2 and 3 lack unity of invention because even though the inventions of these groups require the technical feature of the presence of TpMos in blood, this technical feature is not a special technical feature as it does not make a contribution over the prior art in view of Teh et al. (2022; made of record in IDS filed 2 Sep 2025) or alternately Ng et al. (WO-2019147187-A1; PTO-892). Teh teaches TpMos in peripheral blood (Abstract, pg. 4 section header following col. 1 par. 1). Also, Ng teaches TpMos [0069, 0231, 0263] and teaches that the sample tested can be a blood sample [0053].
Telephonic Election
During a telephone conversation with Zhengyu Feng on 17 Sep 2026 a provisional election was made without traverse to prosecute the invention of Group 2, claims 19-32. Affirmation of this election must be made by applicant in replying to this Office action. Claims 8-11 and 33 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention.
Notice to Joint Inventors
Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be corrected in compliance with 37 CFR 1.48(a) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. A request to correct inventorship under 37 CFR 1.48(a) must be accompanied by an application data sheet in accordance with 37 CFR 1.76 that identifies each inventor by his or her legal name and by the processing fee required under 37 CFR 1.17(i).
Notice of Potential Rejoinder
The examiner has required restriction between product or apparatus claims and process claims. Where applicant elects claims directed to the product/apparatus, and all product/apparatus claims are subsequently found allowable, withdrawn process claims that include all the limitations of the allowable product/apparatus claims should be considered for rejoinder. All claims directed to a nonelected process invention must include all the limitations of an allowable product/apparatus claim for that process invention to be rejoined.
In the event of rejoinder, the requirement for restriction between the product/apparatus claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product/apparatus are found allowable, an otherwise proper restriction requirement between product/apparatus claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product/apparatus claim will not be rejoined. See MPEP § 821.04. Additionally, in order for rejoinder to occur, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product/apparatus claims. Failure to do so may result in no rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.
Priority
The instant application is a 371 of PCT/SG2023/050127 (filed 3 March 2023). The effective filing date used for searching the art is 3 March 2023 for all claims.
Information Disclosure Statement
The information disclosure statement (IDS) submitted on 2 Sep 2025 was filed in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement has been considered by the examiner. A signed copy of the statement is attached with this action.
Specification
The disclosure is objected to because of the following informalities: the abbreviation “CLP” is not defined in the specification and is only defined in Figure 1C as “cecal ligation and puncture”. The specification should be amended to define the abbreviation so that the meaning can be understood using a search of the text. Appropriate correction is required.
This paragraph is not an objection and is included for applicant’s information only. The specification states “Teh, Ye Chean, et al. "Transitional Premonocytes Emerge in the Periphery for Host Defense Against Bacterial Infections." Science Advances, vol. 8, no. 9, American Association for the Advancement of Science (AAAS), Mar. 2022. is hereby incorporated by reference in its entirety.” [0127]. Essential material may not be incorporated by reference from a non-patent reference such as Teh et al., see 37 C.F.R. 1.57(d). Essential material is material that is necessary to (1) provide a written description of the claimed invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and set forth the best mode contemplated by the inventor of carrying out the invention as required by 35 U.S.C. 112(a); (2) describe the claimed invention in terms that particularly point out and distinctly claim the invention as required by 35 U.S.C. 112(b); or (3) describe the structure, material, or acts that correspond to a claimed means or step for performing a specified function as required by 35 U.S.C. 112(f). The Teh et al. reference has not been treated as essential material in this action. If applicant would like to use this reference to provide essential material later in prosecution, applicant is directed to MPEP 608.01(p) for information about how to correct an improper incorporation by reference.
Claim Interpretation
Regarding claims 21, 23-24, 29, and 31-32, the claims recite limitations about where the O-antigen is “from”, such as “E. coli” or specific serotypes and strains. These are interpreted as product-by-process limitations because they define the product based on its method of production (being “from E. coli”, etc.). MPEP 2113 states: "[E]ven though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process." In re Thorpe, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985) (citations omitted).
Claim Rejections - 35 USC § 112(b)
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 19-32 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Regarding claims 19 and 27, these claims both recite the cell population “transitional premonocytes (TpMos)”. The specification defines: “As used herein, a transitional premonocyte (TpMo) is a cell that has the following surface markers: Ly6C-hi, CXCR4-hi, CCR2-lo, CD62L-hi, CD11b-lo , and CD31-hi. Transitional premonocytes (TpMos) are actively proliferating by nature.” [0060]. The terms “hi” and “lo” (presumed to mean “high” and “low”) in the term definition are a relative terms which render the claim indefinite. The cutoffs for the amounts of protein required to fit into the high/low categories are not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Therefore, one of ordinary skill would not be able to clearly identify the boundaries of which cells are claimed because they would not be able to clearly determine whether the protein levels are high/low enough to fall within the term’s definition. Claims 20-26 and 28-32 are also rejected because they depend from claim 19 or 27 and they do not obviate this grounds of rejection. In this action, a cell will be interpreted as a TpMo if they are stated to be one in the reference.
Claim Rejections - 35 USC § 112(a)
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 19-32 rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The functional limitations are not enabled when performing the claimed steps.
The factors to be considered in determining whether a disclosure would require undue experimentation include: (A) The breadth of the claims; (B) The nature of the invention; (C) The state of the prior art; (D) The level of one of ordinary skill; (E) The level of predictability in the art; (F) The amount of direction provided by the inventor; (G) The existence of working examples; and (H) The quantity of experimentation needed to make or use the invention based on the content of the disclosure. In re Wands, 8 USPQ2d, 1400 (CAFC 1988) and MPEP 2164.01.
The breadth of the claims: The claims are drawn to methods comprising a single step of “administering to a subject a therapeutically effective amount of a composition comprising an O-antigen”. The administration has the effects of “treating a bacterial infection” and “wherein the administration of the O-antigen mobilizes transitional premonocytes (TpMos) from a bone marrow into peripheral blood of the subject” (claim 19 and dependent claims) or alternately “mobilizing transitional premonocytes (TpMos) from bone marrow into peripheral blood of a subject” (claim 27 and dependent claims). The bacterial infection can be bacterial sepsis (claim 20).
Dependent claims limit the source and structure of the O antigen that is administered, to being from E. coli (claims 21, 29), being an O-antigen from E. coli O18 serotype or O111 serotype (claims 23, 31), being wherein the E. coli O18 serotype is E. coli UTI89 strain (claims 24, 32), or comprising the structure DGlc-(al-4)-DGal(al-3)-DGlcNAc (claims 22, 30). Dependent claims also limit the dose of O antigen delivered to between 40-400 ng (claims 25, 28).
The specification defines the term “O-antigen” as follows: “The term "O-antigen", also known as" O-specific polysaccharide" or "O-side35 chain", is meant to refer to a major component of the surface lipopolysaccharide (LPS) of Gram-negative bacteria that is highly variable in structure. As used herein, the "O-antigen" may include a reference to the O-antigen itself, the O-antigen as part of an intact lipopolysaccharide (LPS), or the O-antigen as part of an intact LPS on a bacterial cell.” [0058].
The specification defines the term “therapeutically effective amount” as follows: “The term "therapeutically effective amount" refers to the amount of the O-antigen that is required to confer the intended therapeutic effect in the subject, which amount will vary depending on the route of administration, status of infection or sepsis, and possible inclusion of other therapeutics or excipients.” [0077]. The specification does not define the term “intended therapeutic effect” that is used in the specification; however, a reasonable interpretation is that causing disease or illness is outside of the scope of “therapeutic effects”.
The claims recite a broad range of O antigens structures administered including O antigen itself, O antigen as part of LPS, and O antigen on a cell which may be either live or dead, pathogenic or attenuated, etc. The breadth claimed is beyond what is enabled in the specification for performing the functions required by the method.
The nature of the invention: The nature of the invention is an in vivo method that is applied to a subject and includes in vivo outcomes of an administration step.
The state of the prior art: Administration of O antigen, either alone or in the context of a bacteria, was well known in the art at the time of filing; however, this administration was also well known to be harmful to the subject rather than producing the therapeutic effects claimed.
Frasa et al. (1996, “Enhanced protection…”; PTO-892) teaches “mice were inoculated i.p. with either 10^5, 10^6, 10^7, 10^8,or 10^9 CFU of E. coli O18K5 in 0.5 ml of PBS (pH 7.2)… Deaths occurred generally within 24 h” (pg. 766 col. 2 par. 3). Frasa teaches that E. coli O18 also causes infection and disease in humans: “The O18 antigen is one of the four most prevalent O antigens of E. coli strains isolated from bacteremic patients (3, 10, 18)” (pg. 775 par. bridging cols.).
Page et al. (2021, “Equine Peripheral Gene…”; PTO-892) teaches administration by injection of 1,000 ng or less of lipopolysaccharide from E. coli O111:B4, including doses of 10 ng and 100 ng (i.e. within the range of claims 25 and 28) (Abstract, pg. 2 col. 1 par. 3). Page et al. found that the administration was harmful to the subject because “nonweight bearing lameness was noted at doses of 10ng or higher” and lower doses caused neither toxicity in the form of lameness nor a therapeutic effect in the form of changes in mRNA expression (Abstract).
Caroff et al. (WO-2021180972-A1; PTO-892) teaches modified LPS that has been detoxified by being “- devoid of phosphate group at position C1 of the reducing end of their lipid A domain; and - substituted at position C6' of the non-reducing end of their lipid A domain by a hydrophilic moiety, with the proviso that said hydrophilic moiety is not a hydroxyl group” can be used for treating infectious diseases [Abstract]. Caroff teaches a lengthy list of infectious diseases that can be treated [pg. 118 ln. 5- pg. 120 ln. 8], and teaches bacterial infections generally [pg. 118 ln. 8] but does not teach sepsis can be treated by the modified LPS. Caroff teaches that these modifications are required because LPS has drawbacks when used as an adjuvant: “ LPS are mostly naturally toxic and pyrogenic, as they can trigger strong immune responses in the host resulting in fever, uncontrolled production of proinflammatory cytokines, which can often lead to septic shock.” [pg. 3 ln. 28-30]. Caroff teaches that the detoxified LPS differs from classical E. coli molecules by having different fatty acid chains (i.e. it is not from the sources of claims 21, 22-24, 29 and 31-32) [pg. 12 ln. 4-9], and also teaches that E. coli is not in a list of examples of naturally-occurring LPS molecules that are not toxic [pg. 97 ln. 5-16].
Teh et al. (4 March 2022, “Transitional premonocytes…”; IDS filed 2 Sep 2025) is a grace period reference authored by the inventors, as well as others. The reference teaches that “proliferating transitional premonocytes (TpMos), an immediate precursor of mature Ly6Chi monocytes (MatMos), were mobilized into the periphery in response to acute bacterial infection and sepsis.” (Abstract). This TpMos subset was induced by E. coli (i.e. O-antigen) administration via cecal ligation and puncture (Figure 1 and legend). Therefore, Teh teaches administering O antigen in the form of a bacteria to mobilize TpMos, but this cannot be considered a “therapeutically effective amount of an O-antigen” as claimed because the administration causes disease and sepsis as described in the Abstract. Teh does not teach administering O antigen in any other form, it only teaches bacterial infections.
In summary, the art teaches that multiple different versions of O antigen (bacteria, LPS) are toxic rather than therapeutic when administered to subjects. The LPS comprising O antigen can be modified so that it can be used for treating infections, but these modifications mean the O antigen must not be taken from the sources disclosed in the dependent claims. The art does not teach using a therapeutically effective amount of O antigen to mobilize TpMos; it only teaches that this effect occurs during infections and sepsis.
The level of one of ordinary skill: The level of ordinary skill is revealed by the art at the time of filing. Administering an O antigen was within the level of ordinary skill as evidenced by the multiple references teaching this step. However, the level of ordinary skill does not include changing the functional effects that occur when a product is administered. "Products of identical chemical composition can not have mutually exclusive properties." In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). A chemical composition and its properties are inseparable.
The level of predictability in the art: The art teaches there is a high level of predictability that administering unmodified O antigen will be harmful and toxic rather than therapeutic. The art teaches that there is a very low level of predictability that administering a therapeutically effective amount O antigen will mobilize TpMos to the peripheral blood, because there is no evidence that this effect would occur and TpMos mobilization is only known to occur during sepsis.
The amount of direction provided by the inventor: The specification teaches that sepsis remains in need of “new intervention strategies” [0004] because “due to the complexity and rapidity of sepsis progression, current therapies and biomarkers for prediction of outcome remain limited in their success. Despite the advances in supportive measures for sepsis, the mortality rate of sepsis remains high” [0002-0003]. In the summary and detailed description, the specification provides general information on pharmaceutical compositions and administration methods [0072-0103]. However, there is no information about how to formulate or administer the O antigen compositions in order to avoid the art-known effects of toxicity and infection and in order to obtain the claimed therapeutic effects. The specification teaches the therapeutically effective amount “will vary depending on the route of administration, status of infection or sepsis, and possible inclusion of other therapeutics or excipients.” [0077], but does not teach how to determine how to vary the administered amounts based on those variables to achieve a therapeutic effect.
The existence of working examples: Example 1 states: “a population of Ly6Chi proliferative monocytes was detected in the circulation of E. coli-infected and CLP-induced septic mice (Fig. 1A-C).” [0130]. However, an E. coli infection cannot be considered “a therapeutically effective amount of an O-antigen” as claimed because it has a harmful rather than therapeutic effect.
Example 2 “TpMos were only detected under bacteria exposure (Fig. 3A) and not in tested parasitic or viral infection models” [0132].
Example 3 “only the gram-negative E. coli bacteria triggered a substantial number of TpMos into the circulation (Fig, 4A),” [0134]. Example 3 “TpMos were only mobilized upon E. coli infection with an 018 serotype (UT189). MG1655, a laboratory strain of E. coli without the ability to synthesize O-antigen, was unable to trigger the mobilization of TpMos even after restoration of its wildtype 016 structure in different doses (L5: partial restoration, L9: full restoration) (Fig 4B). also It was also confirmed that TpMo mobilization was restricted to the O-antigen serotype as the presence of these cells could also be detected with administration of LPS alone. However, while LPS of the 0111 serotype was able to mobilize TpMos, LPS of the 055 serotype was unable to (Fig. 4C), even though both serotypes have been documented to be enteropathogenic strains. Preliminary analysis of the O-antigen structures of O18 and O111, which induced the greatest number of TpMos into the circulation, revealed a common glycan structure as indicated in Fig. 4D, suggesting that certain O-antigen glycan structures were able to induce the release of TpMos into the circulation.” [0135] The description of Figure 4C only states “mice [were] challenged with LPS of different O-antigens” [0043] and does not describe the administration method, the dose used, or whether there was a toxic effect on the mice.
Example 4 “blood samples were collected from septic patients in ICU to check for the presence of TpMos. The preliminary data shows that patients without TpMos in their circulation compromised some time later, while some patients who managed to be discharged retained TpMos in their circulation as shown in Fig. 17” [138].
There are no examples of the claimed invention with the effect of “treating a bacterial infection.” Example 3 might provide a single example of “method of mobilizing transitional premonocytes (TpMos) from bone marrow into peripheral blood of a subject, the method comprising administering to the subject a therapeutically effective amount of an O-antigen”, but it is uncertain whether the O antigen administered is truly “a therapeutically effective amount” or whether the administration is harmful and causes inflammation, fever, and other toxic effects as taught in the art.
The quantity of experimentation needed to make or use the invention: A person of ordinary skill in the art would have to perform extensive in vivo experimentation in humans or animal models of bacterial infection or TpMo mobilization in order to demonstrate whether the invention could be used for the claimed purpose. Given that the art teaches that administration of O-antigen causes toxicity or infection rather than therapeutic effect, one of ordinary skill in the art would have a high probability of achieving the art-disclosed effect instead of the claimed effect. The specification also provides several examples of administering a non-therapeutic amount of O antigen to result in an infection [Examples 1-3]. Administering LPS as in Example 3 cannot be replicated by one of ordinary skill in the art because no information was provided about the administration protocol used and also the specification did not disclose whether the LPS administration was a non-therapeutic dose that caused toxicity. To administer the O antigen with a reasonable expectation of success, extensive screening and trial and error would be required to understand which dosages, formulations, and administration routes of O antigen achieve the claimed effects of treating bacterial infection and mobilizing TpMos to the peripheral blood.
The standard of an enabling disclosure is not the ability to make and test if the invention works but one of the ability to make and use with a reasonable expectation of success and without undue experimentation. A patent is granted for a completed invention, not the general suggestion of an idea (MPEP 2164.03 and Chiron Corp. v. Genentech Inc., 363 F.3d 1247, 1254, 70 USPQ2d 1321, 1325-26 (Fed. Cir. 2004). The instant specification is not enabling because one cannot follow the guidance presented therein, or within the art at the time of filing, and practice the claimed method without first making a substantial inventive contribution.
The amount of experimentation required for enabling guidance, commensurate in scope with what is claimed, goes beyond what is considered ‘routine' within the art, and constitutes undue further experimentation in order to use the method with a reasonable expectation of successfully treating bacterial infection or mobilizing TpMos when administering a therapeutic dose of O antigen. Therefore, claims 19-32 are rejected under 35 U.S.C. §112(a) or 35 U.S.C. §112, first paragraph, for failing to meet the enablement requirement.
Claims 19-32 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention.
MPEP 2163 states:
An original claim may lack written description support when (1) the claim defines the invention in functional language specifying a desired result but the disclosure fails to sufficiently identify how the function is performed or the result is achieved or (2) a broad genus claim is presented but the disclosure only describes a narrow species with no evidence that the genus is contemplated. See Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1349-50 (Fed. Cir. 2010) (en banc). The written description requirement is not necessarily met when the claim language appears in ipsis verbis in the specification. "Even if a claim is supported by the specification, the language of the specification, to the extent possible, must describe the claimed invention so that one skilled in the art can recognize what is claimed. The appearance of mere indistinct words in a specification or a claim, even an original claim, does not necessarily satisfy that requirement." Enzo Biochem, Inc. v. Gen-Probe, Inc., 323 F.3d 956, 968, 63 USPQ2d 1609, 1616 (Fed. Cir. 2002).
Thus, the written description requirement may be satisfied through disclosure of function and minimal structure when there is a well-established correlation between structure and function. In contrast, without such a correlation, the capability to recognize or understand the structure from the mere recitation of function and minimal structure is highly unlikely. In this latter case, disclosure of function alone is little more than a wish for possession; it does not satisfy the written description requirement. See Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406 (written description requirement not satisfied by merely providing "a result that one might achieve if one made that invention"); In re Wilder, 736 F.2d 1516, 1521, 222 USPQ 369, 372-73 (Fed. Cir. 1984) (affirming a rejection for lack of written description because the specification does "little more than outline goals appellants hope the claimed invention achieves and the problems the invention will hopefully ameliorate").
The claims are drawn to methods comprising a single step of “administering to a subject a therapeutically effective amount of a composition comprising an O-antigen”. The administration has the effects of “treating a bacterial infection” and “wherein the administration of the O-antigen mobilizes transitional premonocytes (TpMos) from a bone marrow into peripheral blood of the subject” (claim 19 and dependent claims) or alternately “mobilizing transitional premonocytes (TpMos) from bone marrow into peripheral blood of a subject” (claim 27 and dependent claims). The bacterial infection can be bacterial sepsis (claim 20).
Dependent claims limit the source and structure of the O antigen that is administered, to being from E. coli (claims 21, 29), being an O-antigen from E. coli O18 serotype or O111 serotype (claims 23, 31), being wherein the E. coli O18 serotype is E. coli UTI89 strain (claims 24, 32), or comprising the structure DGlc-(al-4)-DGal(al-3)-DGlcNAc (claims 22, 30). Dependent claims also limit the dose of O antigen delivered to between 40-400 ng (claims 25, 28).
The specification defines the term “O-antigen” as follows: “The term "O-antigen", also known as" O-specific polysaccharide" or "O-side35 chain", is meant to refer to a major component of the surface lipopolysaccharide (LPS) of Gram-negative bacteria that is highly variable in structure. As used herein, the "O-antigen" may include a reference to the O-antigen itself, the O-antigen as part of an intact lipopolysaccharide (LPS), or the O-antigen as part of an intact LPS on a bacterial cell.” [0058].
The specification defines the term “therapeutically effective amount” as follows: “The term "therapeutically effective amount" refers to the amount of the O-antigen that is required to confer the intended therapeutic effect in the subject, which amount will vary depending on the route of administration, status of infection or sepsis, and possible inclusion of other therapeutics or excipients.” [0077]. The specification does not define the term “intended therapeutic effect” that is used in the specification; however, a reasonable interpretation is that causing disease or illness is outside of the scope of “therapeutic effects”.
The claims recite a broad range of O antigens structures administered including O antigen itself, O antigen as part of LPS, and O antigen on a cell which may be either live or dead, pathogenic or attenuated, etc. The breadth claimed is beyond what is enabled in the specification for performing the functions required by the method.
The teachings of the specification and the art were discussed above in the enablement rejection (par. 24-29 and 32-37) and also are included in this rejection.
The specification does not disclose any structure correlated with the function “treating a bacterial infection”. There are no examples in the specification with the effect of “treating a bacterial infection”, and there is also no detailed description elsewhere in the specification of a protocol that is expected to achieve this effect. The art also does not show that there is a known structure correlated with the function of “treating a bacterial infection”; instead, the art shows that a subset of O-antigens (specifically, live bacterial cells comprising O-antigens) cause bacterial infections. The specification also does not demonstrate a representative number of species within the genus of administration steps claimed. There are no examples in the specification with the effect of “treating a bacterial infection” so it cannot be considered a representative number of species, and there is also no detailed description elsewhere in the specification of a protocol to achieve this effect. Therefore, when evaluating the specification in the context of the prior art at the time of filing, one having ordinary skill in the art at the time of filing would have concluded that the specification has not demonstrated possession of a method with the effect of treating bacterial infection comprising the step of administering O antigen in any formulation, dose, or administration method.
Also, the specification discloses that the structure correlated with the function of “mobilizing transitional premonocytes (TpMos) from bone marrow into peripheral blood of a subject” is much narrower than is claimed. The specification demonstrates that not all O-antigens can perform this function, but instead “revealed a common glycan structure as indicated in Fig. 4D, suggesting that certain O-antigen glycan structures were able to induce the release of TpMos into the circulation.” [0135]. Other O-antigen structures, such as those on other bacterial species [0134, Figure 4A] or other serotypes of E. coli [0135, Figure 4C], do not have this effect. The disclosed structures capable of “mobilizing transitional premonocytes (TpMos) from bone marrow into peripheral blood of a subject” is not representative of the genus because the function requires a specific glycan structure that is not found on most O antigen structures or even most E. coli serotypes. Therefore, when evaluating the specification in the context of the prior art at the time of filing, one having ordinary skill in the art at the time of filing would have concluded that the specification has not demonstrated possession of a method with the effect of mobilizing transitional premonocytes (TpMos) from bone marrow into peripheral blood of a subject comprising the step of administering O antigen in any formulation, dose, or administration method, and has only demonstrated that possession of O antigen structures comprising the structure DGlc-(al-4)-DGal(al-3)-DGlcNAc or from E. coli 018 serotype or 0111 serotype that have this function.
Also, the specification does not disclose any structures correlated with the function of being a “therapeutically effective amount.” There are no examples in the specification showing a therapeutic effect; the specification only shows that bacteria comprising O antigen can cause infection and sepsis [Examples 1-4] and also administers LPS alone but is silent on the effect of administration [0043, 0135, Figure 4C]. However, the art teaches that both of these structures are well known to be toxic and not therapeutic. The specification also does not demonstrate a representative number of species within the genus of administration steps claimed. There are no examples in the specification with a therapeutic effect so it cannot be considered a representative number of species and there is also no detailed description elsewhere in the specification of a protocol to achieve this effect. Therefore, when evaluating the specification in the context of the prior art at the time of filing, one having ordinary skill in the art at the time of filing would have concluded that the specification has not demonstrated possession of a method with a therapeutic effect comprising the step of administering O antigen in any formulation, dose, or administration method.
Therefore, claims 19-32 are rejected for failing to demonstrate possession of the claimed invention.
Conclusion
No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to AMELIA N DICKENS whose telephone number is (571)272-0381. The examiner can normally be reached M-F 8:30-4:30 (EDT/EST).
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Samira Jean-Louis can be reached at (571) 270-3503. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
AMELIA N DICKENS
Examiner
Art Unit 1645
/AMELIA NICOLE DICKENS/Examiner, Art Unit 1645